L’essai clinique de phase 3 CALYPSO, mené par AstraZeneca via sa division Alexion, spécialisée dans les maladies rares, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback